Biper Therapeutics

BiPER Therapeutics opens a new therapeutic pathway in the treatment of cancers. Our first clinical candidate BPR001-615 is a first-in-class oral small molecule to treat gastro-intestinal tumors by pushing cancers cells to burn out. BPR001 inhibits BiP, a key protein involved in cancer cells survival and associated with very poor prognosis of patients when overexpressed in tumors and in plasma of patients. BPR001-615 has been developed to treat the 50% of BIP+ patients through precision medicine approach based on overexpression level of BiP in plasma of patients. BPR001-615 has been developed as an oral drug in monotherapy or in combination with standards of care to improve patient outcomes. In preclinical studies, patent-protected data demonstrate that BPR001 is effective in monotherapy outperforming standards of care and enhances a wide range of standard of care agents like chemotherapies, targeted therapies and immunotherapies. We aim at quickly expand worldwide to develop the company and propose investors to join us in this fantastic journey, create value together and bring our unique therapeutic solutions to patients